Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma
Phase II Trial of Maintenance Apatinib After Second-Line Treatment for Locally Recurrent or Metastatic Nasopharyngeal Carcinoma
Sponsor: Guangxi Naxishan Hospital
A PHASE2 clinical study on Nasopharyngeal Carcinoma, this trial is ongoing. The trial is conducted by Guangxi Naxishan Hospital and has accumulated 7 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Jun 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Guangxi Naxishan Hospital
- Guilin Medical University, China
- People's Hospital of Guangxi Zhuang Autonomous Region
- Wuzhou Red Cross Hospital
For direct contact, visit the study record on ClinicalTrials.gov .